Confirmation and expansion of the phenotype of the TCEAL1-related neurodevelopmental disorder.


Journal

European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235

Informations de publication

Date de publication:
10 Jan 2024
Historique:
received: 07 09 2023
accepted: 19 12 2023
revised: 30 11 2023
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 10 1 2024
Statut: aheadofprint

Résumé

Numerous contiguous gene deletion syndromes causing neurodevelopmental disorders have previously been defined using cytogenetics for which only in the current genomic era the disease-causing genes have become elucidated. One such example is deletion at Xq22.2, previously associated with a neurodevelopmental disorder which has more recently been found to be caused by de novo loss-of-function variants in TCEAL1. So far, a single study reported six unrelated individuals with this monogenetic disorder, presenting with syndromic features including developmental delay especially affecting expressive speech, intellectual disability, autistic-like behaviors, hypotonia, gait abnormalities and mild facial dysmorphism, in addition to ocular, gastrointestinal, and immunologic abnormalities. Here we report on four previously undescribed individuals, including two adults, with de novo truncating variants in TCEAL1, identified through trio exome or genome sequencing, further delineating the phenotype of the TCEAL1-related disorder. Whereas overall we identify similar features compared to the original report, we also highlight features in our adult individuals including hyperphagia, obesity, and endocrine abnormalities including hyperinsulinemia, hyperandrogenemia, and polycystic ovarian syndrome. X chromosome inactivation and RNA-seq studies further provide functional insights in the molecular mechanisms. Together this report expands the phenotypic and molecular spectrum of the TCEAL1-related disorder which will be useful for counseling of newly identified individuals and their families.

Identifiants

pubmed: 38200082
doi: 10.1038/s41431-023-01530-6
pii: 10.1038/s41431-023-01530-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : ZonMw (Netherlands Organisation for Health Research and Development)
ID : 09150172110002
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : 433158657

Informations de copyright

© 2024. The Author(s).

Références

Yamamoto T, Wilsdon A, Joss S, Isidor B, Erlandsson A, Suri M, et al. An emerging phenotype of Xq22 microdeletions in females with severe intellectual disability, hypotonia and behavioral abnormalities. J Hum Genet. 2014;59:300–6.
doi: 10.1038/jhg.2014.21 pubmed: 24646727
Hijazi H, Coelho FS, Gonzaga-Jauregui C, Bernardini L, Mar SS, Manning MA, et al. Xq22 deletions and correlation with distinct neurological disease traits in females: Further evidence for a contiguous gene syndrome. Hum Mutat. 2020;41:150–68.
doi: 10.1002/humu.23902 pubmed: 31448840
Inoue K. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics. 2005;6:1–16.
doi: 10.1007/s10048-004-0207-y pubmed: 15627202
Labonne JDJ, Graves TD, Shen Y, Jones JR, Kong IK, Layman LC, et al. A microdeletion at Xq22.2 implicates a glycine receptor GLRA4 involved in intellectual disability, behavioral problems and craniofacial anomalies. BMC Neurol. 2016;16:132.
doi: 10.1186/s12883-016-0642-z pubmed: 27506666 pmcid: 4979147
Hijazi H, Reis LM, Pehlivan D, Bernstein JA, Muriello M, Syverson E, et al. TCEAL1 loss-of-function results in an X-linked dominant neurodevelopmental syndrome and drives the neurological disease trait in Xq22.2 deletions. Am J Hum Genet. 2022;109:2270–82.
doi: 10.1016/j.ajhg.2022.10.007 pubmed: 36368327 pmcid: 9748253
Deng R, Medico-Salsench E, Nikoncuk A, Ramakrishnan R, Lanko K, Kühn NA, et al. AMFR dysfunction causes autosomal recessive spastic paraplegia in human that is amenable to statin treatment in a preclinical model. Acta Neuropathol (Berl). 2023;146:353–68.
doi: 10.1007/s00401-023-02579-9 pubmed: 37119330
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–30.
doi: 10.1002/humu.22844 pubmed: 26220891 pmcid: 4833888
Falb RJ, Müller AJ, Klein W, Grimmel M, Grasshoff U, Spranger S, et al. Bi-allelic loss-of-function variants in KIF21A cause severe fetal akinesia with arthrogryposis multiplex. J Med Genet. 2023;60:48–56.
doi: 10.1136/jmedgenet-2021-108064 pubmed: 34740919
Deschauer M, Hengel H, Rupprich K, Kreiß M, Schlotter-Weigel B, Grimmel M, et al. Bi-allelic truncating mutations in VWA1 cause neuromyopathy. Brain J Neurol. 2021;144:574–83.
doi: 10.1093/brain/awaa418
Gribnau J, Stefan Barakat T. X-chromosome inactivation and its implications for human disease [Internet]. Genetics; 2017 Mar [cited 2023 Aug 15]. Available from: https://doi.org/10.1101/076950 .
Wilke CO. Transcriptional robustness complements nonsense-mediated decay in humans. PLoS Genet. 2011;7:e1002296.
doi: 10.1371/journal.pgen.1002296 pubmed: 22022274 pmcid: 3192817
Lau AW, Brown CJ, Peñaherrera M, Langlois S, Kalousek DK, Robinson WP. Skewed X-chromosome inactivation is common in fetuses or newborns associated with confined placental mosaicism. Am J Hum Genet. 1997;61:1353–61.
doi: 10.1086/301651 pubmed: 9399909 pmcid: 1716095
Growth reference 5-19 years - BMI-for-age (5-19 years) [Internet]. [cited 2023 Aug 15]. Available from: https://www.who.int/tools/growth-reference-data-for-5to19-years/indicators/bmi-for-age .

Auteurs

Fatimah Albuainain (F)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Yuwei Shi (Y)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Sarah Lor-Zade (S)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Ulrike Hüffmeier (U)

Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.

Melissa Pauly (M)

Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.

André Reis (A)

Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany.
Centre for Rare Diseases Erlangen (ZSEER), Erlangen, Germany.

Laurence Faivre (L)

Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Fédération Hospitalo-Universitaire TRANSLAD et Institut GIMI, Dijon Bourgogne University Hospital, F-21000, Dijon, France.
Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, F-21000, Dijon, France.

Julien Maraval (J)

Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, F-21000, Dijon, France.
Centre de Référence Déficiences Intellectuelles de causes rares, Dijon Bourgogne University Hospital, F-21000, Dijon, France.

Ange-Line Bruel (AL)

Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, F-21000, Dijon, France.
Functional Unit of Innovative Diagnosis for Rare Diseases, Dijon Bourgogne University Hospital, F-21000, Dijon, France.

Frédéric Tran Mau Them (FTM)

Inserm UMR1231 team GAD, University of Burgundy and Franche-Comté, F-21000, Dijon, France.
Functional Unit of Innovative Diagnosis for Rare Diseases, Dijon Bourgogne University Hospital, F-21000, Dijon, France.

Tobias B Haack (TB)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Centre for Rare Diseases, University of Tübingen, Tübingen, Germany.

Ute Grasshoff (U)

Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.

Veronka Horber (V)

Department of Pediatric Neurology and Developmental Medicine, University Children's Hospital Tübingen, Tübingen, Germany.

Rachel Schot (R)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
Discovery Unit, Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Marjon van Slegtenhorst (M)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Martina Wilke (M)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.

Tahsin Stefan Barakat (TS)

Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands. t.barakat@erasmusmc.nl.
Discovery Unit, Department of Clinical Genetics, Erasmus MC University Medical Center, Rotterdam, The Netherlands. t.barakat@erasmusmc.nl.
ENCORE Expertise Center for Neurodevelopmental Disorders, Erasmus Medical Center, Rotterdam, The Netherlands. t.barakat@erasmusmc.nl.

Classifications MeSH